• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by PDS Biotechnology Corporation (Amendment)

    8/27/21 8:48:51 AM ET
    $PDSB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PDSB alert in real time by email
    SC 13G/A 1 pdsb-sg13a_081321.htm AMENDMENT TO FORM SC 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Amendment No. 1

      

    Under the Securities Exchange Act of 1934

     

      PDS BIOTECHNOLOGY CORPORATION  
      (Name of Issuer)  
         
     

    Common Stock, par value $0.00033 per share

     

     
      (Title of Class of Securities)  
         
      279870109  
      (CUSIP Number)  
         
      August 13, 2021  
      (Date of Event Which Requires Filing of this Statement)  
         

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed

     

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

     

    The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

      

     

     

     

     

    CUSIP No. 279870109   

     

    1.

    Names of Reporting Persons. AIGH Capital Management, LLC

    I.R.S. Identification Nos. of above persons (entities only).

     

     27-4413262

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)  ☐

    (b)  ☒

    3.

    SEC Use Only

     

    4.

    Citizenship of Place of Organization

     

    Maryland

    Number of Shares

    Beneficially

    Owned by Each

    Reporting  Person

    With

    5.

    Sole Voting Power 

     

    1,135,398

      6.

    Shared Voting Power

     

     

      7. 

    Sole Dispositive Power 

     

    1,135,398

      8.

    Shared Dispositive Power

     

     

    9.

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    1,135,398

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares  ☐

     

     

    11.

    Percent of Class Represented by Amount in Row 9

     

    3.99%

    12.

    Type of Reporting Person (See Instructions)

     

    OO

           

     

     

     

      

    CUSIP No.  279870109   

     

    1.

    Names of Reporting Persons. AIGH Investment Partners, L.L.C.

    I.R.S. Identification Nos. of above persons (entities only).

     

     

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)  ☐

    (b)  ☒

    3.

    SEC Use Only

     

    4.

    Citizenship of Place of Organization

     

    Delaware

    Number of Shares

    Beneficially

    Owned by Each

    Reporting  Person

    With

    5.

    Sole Voting Power 

     

    120,000

      6.

    Shared Voting Power

     

     

      7. 

    Sole Dispositive Power 

     

    120,000

      8.

    Shared Dispositive Power

     

     

    9.

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    120,000

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares  ☐

     

     

    11.

    Percent of Class Represented by Amount in Row 9

     

    .42%

    12.

    Type of Reporting Person (See Instructions)

     

    OO

           

      

     

     

      

    CUSIP No.  279870109   

     

    1.

    Names of Reporting Persons. Orin Hirschman

    I.R.S. Identification Nos. of above persons (entities only).

     

     

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)  ☐

    (b)  ☒

    3.

    SEC Use Only

     

    4.

    Citizenship of Place of Organization

     

    United States

    Number of Shares

    Beneficially

    Owned by Each

    Reporting  Person

    With

    5.

    Sole Voting Power 

     

    1,275,398

      6.

    Shared Voting Power

     

     

      7. 

    Sole Dispositive Power 

     

    1,275,398

      8.

    Shared Dispositive Power

     

     

    9.

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    1,275,398

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares  ☐

     

     

    11.

    Percent of Class Represented by Amount in Row 9

     

    4.49%

    12.

    Type of Reporting Person (See Instructions)

     

    IN

           

      

     

     

     

    ITEM 1:

     

    (a)  Name of Issuer:

     

    PDS Biotechnology Corporation

     

    (b)  Address of Issuer’s Principal Executive Offices:

                          

    200 Connell Drive, Suite 1600, Berkeley Heights, NJ 07922

     

    ITEM 2:

     

    (a)  Name of Person Filing:

     

    This Schedule 13G is being jointly filed by each of the following persons pursuant to Rule 13d-1 promulgated by the Securities and Exchange Commission pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the “Act”):

     

    (i)   AIGH Capital Management, LLC, a Maryland limited liability company ("AIGH LP"), as an Advisor or Sub-Advisor with respect to shares of Common Stock (as defined in Item 2(d) below) held by AIGH Investment Partners, L.P. and WVP Emerging Manger Onshore Fund, LLC;

     

    (ii)  

    AIGH Investment Partners, L.L.C., a Delaware limited liability company ("AIGH LLC"), with respect to shares of Common Stock (as defined in Item 2(d) below) directly held by it;

     

    (iii)   Mr. Orin Hirschman ("Mr. Hirschman"), who is the Managing Member of AIGH Capital Management, LLC and president of AIGH LLC, with respect to shares of Common Stock indirectly held by AIGH LP, directly by AIGH LLC and Mr. Hirschman and his family directly.

     

    AIGH Capital Management LLC., AIGH Investment Partners LLC, and Mr. Hirschman are hereinafter sometimes collectively referred to as the "Reporting Persons." Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

     

    (b)  Address of Principal Business Office or, if None, Residence:

     

    The principal office and business address of AIGH Investment Partners, L.P., AIGH Investment Partners LLC, and Mr. Hirschman is:

     

    6006 Berkeley Avenue

    Baltimore MD 21209

     

    (c)  Citizenship:

     

    See Item 2(a) above and Item 4 of each cover page.

     

    (d)  Title of Class of Securities:

     

    Common Stock, par value $0.00033 per share

     

    (e)  CUSIP Number:

     

    279870109  

     

     

     

     

    ITEM 3:   IF THIS STATEMENT IS FILED PURSUANT TO §§240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

     

      (a)      ☐        Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
           
      (b)  ☐  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
           
      (c)  ☐  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
           
      (d)  ☐  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
           
      (e)  ☐  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f)  ☐  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g)  ☐  A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
           
      (h)  ☐  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i)  ☐  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j)  ☐  A non-U.S. institution, in accordance with §240.13d-1(b)(1)(ii)(J);
           
      (k)  ☐  Group, in accordance with §240.13d-1(b)(1)(ii)(K).
         

     

     If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ___________________________.

     

    ITEM 4:   OWNERSHIP.

     

    See Item s 5,6,7,8 and 9 of each cover page.

     

    ITEM 5:   OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒

     

    ITEM 6:   OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

     

    Not applicable.

     

    ITEM 7:   IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

     

    Not applicable.

     

    ITEM 8:   IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

     

    Not applicable.

     

    ITEM 9:   NOTICE OF DISSOLUTION OF GROUP.

     

    Not applicable.

     

    ITEM 10:  CERTIFICATIONS.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

         
           
    Dated: August 27, 2021 By: /s/ Orin Hirschman  
        Orin Hirschman,  
        Individually and as (a) managing member of AIGH Capital Management LLC.: and (b) president of AIGH Investment Partners LLC.  
           

     

     

    Get the next $PDSB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PDSB

    DatePrice TargetRatingAnalyst
    11/1/2022$10.00Buy
    B. Riley Securities
    8/12/2021$20.00 → $15.00Buy
    HC Wainwright & Co.
    6/28/2021$25.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PDSB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      PRINCETON, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that on May 5, 2025, PDS Biotech granted a nonstatutory stock option to purchase 5,000 shares of common stock to an employee in its clinical department as a material inducement to such employee's employment and in accordance with Nasdaq Listing Rule 5635(c)(4) and PDS Biotech's 2019 Inducement Plan, as amended, which was adopted on June 17, 2019, and provides for the granting of equity awards to new employees of PDS Biotech. The stock option

      5/9/25 4:05:00 PM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

      PRINCETON, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and infectious diseases, today provided updates on preclinical immune response data with a novel, investigational Infectimune® based flu vaccine that were featured at the American Association of Immunologists' IMMUNOLOGY2025™ Annual Meeting, which took place May 3-7, 2025, in Honolulu, Hawaii. As previously announced, on Sunday, May 4, 2025, Andrea Sant, Ph.D., Professor of Microbiology and Immunology at the University of Rochester Medical Center, presented

      5/8/25 8:00:00 AM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results

      PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call to report financial results for the quarter ended March 31, 2025, and provide a clinical programs update on Wednesday, May 14, 2025 at 8:00 a.m. Eastern Time. Conference Call Details Date: May 14, 2025Time: 8:00 a.m. Eastern TimeDial-in: 1-877-704-4453 (Domestic) or 1-201-389-0920 (International) Webcast Registration: Click HereCall MeTM Registration: Click Here (Available 15 minutes prior to ca

      5/7/25 8:00:00 AM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PDSB
    Financials

    Live finance-specific insights

    See more
    • PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results

      PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call to report financial results for the quarter ended March 31, 2025, and provide a clinical programs update on Wednesday, May 14, 2025 at 8:00 a.m. Eastern Time. Conference Call Details Date: May 14, 2025Time: 8:00 a.m. Eastern TimeDial-in: 1-877-704-4453 (Domestic) or 1-201-389-0920 (International) Webcast Registration: Click HereCall MeTM Registration: Click Here (Available 15 minutes prior to ca

      5/7/25 8:00:00 AM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results

      PRINCETON, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call to report financial results for the year ended December 31, 2024, and provide a clinical programs update on Thursday, March 27, 2025, at 8:00 a.m. Eastern Time. Conference Call Details Date: March 27, 2025Time: 8:00 a.m. Eastern TimeDial-in: 1-877-704-4453 (Domestic) or 1-201-389-0920 (International)Webcast Registration: Click HereCall Me™ Registration: Click Here (Available 15 minutes prio

      3/18/25 8:00:00 AM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

      Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that it has received the official minutes from its meeting with the U.S. Food and Drug Administration ("FDA") regarding next steps in its planned Phase 3 clinical trial of its Versamune® based investigational immunotherapy designed to stimulate a targeted T cell attack against HPV

      8/1/24 7:45:00 AM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PDSB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Freitag Gregory Gene bought $25,000 worth of shares (15,060 units at $1.66), increasing direct ownership by 33% to 61,213 units (SEC Form 4)

      4 - PDS Biotechnology Corp (0001472091) (Issuer)

      3/3/25 4:45:42 PM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Glover Stephen C. bought $25,001 worth of shares (15,061 units at $1.66), increasing direct ownership by 24% to 78,851 units (SEC Form 4)

      4 - PDS Biotechnology Corp (0001472091) (Issuer)

      3/3/25 4:45:20 PM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Freitag Gregory Gene

      4 - PDS Biotechnology Corp (0001472091) (Issuer)

      6/25/24 4:05:13 PM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PDSB
    SEC Filings

    See more
    • PDS Biotechnology Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - PDS Biotechnology Corp (0001472091) (Filer)

      5/8/25 8:05:20 AM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFR14A filed by PDS Biotechnology Corporation

      DEFR14A - PDS Biotechnology Corp (0001472091) (Filer)

      5/5/25 4:15:23 PM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PDS Biotechnology Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - PDS Biotechnology Corp (0001472091) (Filer)

      5/2/25 8:00:19 AM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PDSB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Freitag Gregory Gene bought $25,000 worth of shares (15,060 units at $1.66), increasing direct ownership by 33% to 61,213 units (SEC Form 4)

      4 - PDS Biotechnology Corp (0001472091) (Issuer)

      3/3/25 4:45:42 PM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Glover Stephen C. bought $25,001 worth of shares (15,061 units at $1.66), increasing direct ownership by 24% to 78,851 units (SEC Form 4)

      4 - PDS Biotechnology Corp (0001472091) (Issuer)

      3/3/25 4:45:20 PM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PDSB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by PDS Biotechnology Corporation (Amendment)

      SC 13G/A - PDS Biotechnology Corp (0001472091) (Subject)

      5/8/24 2:22:56 PM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by PDS Biotechnology Corporation

      SC 13G - PDS Biotechnology Corp (0001472091) (Subject)

      1/29/24 5:26:00 PM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by PDS Biotechnology Corporation (Amendment)

      SC 13G/A - PDS Biotechnology Corp (0001472091) (Subject)

      8/27/21 8:48:51 AM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PDSB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities initiated coverage on PDS Biotechnology with a new price target

      B. Riley Securities initiated coverage of PDS Biotechnology with a rating of Buy and set a new price target of $10.00

      11/1/22 6:20:52 AM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on PDS Biotechnology with a new price target

      HC Wainwright & Co. reiterated coverage of PDS Biotechnology with a rating of Buy and set a new price target of $15.00 from $20.00 previously

      8/12/21 11:00:21 AM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on PDS Biotechnology with a new price target

      Cantor Fitzgerald initiated coverage of PDS Biotechnology with a rating of Overweight and set a new price target of $25.00

      6/28/21 7:38:35 AM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PDSB
    Leadership Updates

    Live Leadership Updates

    See more
    • PDS Biotech Appoints Stephan Toutain as Chief Operating Officer

      PRINCETON, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced the appointment of Stephan Toutain, MS, MBA, as Chief Operating Officer (COO), effective as of May 1, 2024. "We are thrilled to welcome Stephan to the PDS Biotech team as Chief Operating Officer. His invaluable experience spans many aspects of the life sciences industry, from drug development to commercialization, providing a wealth of knowledge to our team," said Frank Bedu-Addo, PhD, Pre

      5/2/24 8:00:00 AM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer

      PRINCETON, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or "the Company"), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary T cell activating platforms, today announced the appointment of Kirk V. Shepard, M.D., as Chief Medical Officer, effective January 22, 2024. Dr. Shepard succeeds Lauren V. Wood, M.D., who is retiring from the Company after five years in the role. Dr. Wood will continue to be available to PDS Biotech during a handover period to facilitate the transition of the role to Dr. Shepard. "We are please

      1/22/24 4:45:19 PM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer

      Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and

      11/28/23 8:30:00 AM ET
      $APYX
      $PDSB
      $SSKN
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations